Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

FDA Fast-Track Program Ends as Biotech Approval Calendar Enters a High-Risk Stretch

The FDA’s Fast-Track decision adds uncertainty to biotech timelines as priority reviews and target dates crowd the calendar through year-end…

Nov 12, 2026
Pharmaceutical

Mirum Pharmaceuticals Keeps Buy Rating After Positive Trial Data

H.C. Wainwright reiterated its Buy rating on $MIRM after positive trial data, keeping attention on Mirum’s rare-disease pipeline.

Nov 11, 2026
Pharmaceutical

Celcuity’s REVTORPYK Launch Builds Momentum as Competition and Regulation Loom

Celcuity says REVTORPYK is off to a strong early start, but regulatory complexity, competition and infrastructure needs remain key execution…

Nov 11, 2026
Pharmaceutical

Alvotech Enters Pivotal Quarter With Three FDA Biosimilar Decisions Ahead

Alvotech faces three anticipated FDA decisions in the fourth quarter, creating a pivotal test for its commercial outlook and risk profile.

Nov 11, 2026
Pharmaceutical

Capricor Therapeutics Shares Rise Ahead of Nov. 22 FDA Decision

CAPR shares are drawing speculative interest ahead of the FDA’s Nov. 22 decision, creating a binary catalyst for traders.

Nov 11, 2026
Pharmaceutical

Gossamer Bio Price Target Cut as Analysts Diverge on NDA Outlook

Wedbush lowered its Gossamer Bio price target over regulatory uncertainty, while H.C. Wainwright and Chardan remain bullish on the NDA path.

Nov 11, 2026
Pharmaceutical

AstraZeneca’s Omniose Acquisition Signals Continued Appetite for Preclinical Biotech Deals

AstraZeneca’s acquisition of Omniose highlights its pipeline-building strategy and the pharmaceutical sector’s continued interest in preclin…

Nov 10, 2026
Pharmaceutical

Zura Bio Plunges 76% After Tibulizumab Fails Phase 2 Hidradenitis Trial

Zura Bio shares plunged 76% after tibulizumab failed a Phase 2 hidradenitis trial, prompting the company to discontinue development for the …

Nov 9, 2026
Pharmaceutical

Vir Biotechnology’s Positive Phase 3 Hepatitis Delta Data Put $VIR in Focus

Vir Biotechnology’s positive Phase 3 ECLIPSE 1 readout may strengthen its regulatory outlook, but approval and valuation upside remain uncer…

Nov 9, 2026
Pharmaceutical

Eli Lilly’s Foundayo Sleep Apnea Results Set Up 2026 FDA Filing

Positive late-stage sleep apnea data could broaden Eli Lilly’s Foundayo franchise beyond weight management, with a U.S. filing planned by ye…

Nov 9, 2026
Pharmaceutical

RBC Initiates Eupraxia Coverage With Outperform Rating as Analysts Cite EP-104GI Data

RBC begins coverage of Eupraxia with an Outperform rating as analysts point to positive Phase 2b EP-104GI data and renewed investor interest…

Nov 9, 2026
Pharmaceutical

Genmab Shares Rise 4% After FDA Approves Partnered Cancer Drug

Genmab shares rose 4% after FDA approval of a Johnson & Johnson-partnered cancer drug, sharpening focus on its oncology strategy.

Nov 9, 2026